Category Archives: Transhuman News

Best Psoriasis Cream - Psoriasis Guttate Natural Remedies
http://bit.ly/1rDg0Zx Click now to find out about removing psoriasis completely in under 3 days! It is quick and really is successful. Best psoriasis cream. ...

By: Syreeta Tridenti

Original post:
Best Psoriasis Cream - Psoriasis Guttate Natural Remedies - Video

Cure For Psoriasis On Scalp - Psoriasis Arthritis Treatment Diet
http://bit.ly/VU8kTI Click here to learn about how to get rid of psoriasis completely in less than one week. It #39;s fast and effective and really is effective!...

By: Clelia Ascheman

Excerpt from:
Cure For Psoriasis On Scalp - Psoriasis Arthritis Treatment Diet - Video

Psoriasis Warts
Click on the link - http://tinyurl.com/lyndwjd - Makeup, Face, Eyes, Lips, Tools Accessories, Makeup Sets Kits, Makeup Bags Accessories, Perfume Cologne, Women, Men, Unisex, Skin Care,...

By:

See the original post here:
Psoriasis Warts - Video

Dovonex Cream For Psoriasis
Click on the link - http://tinyurl.com/lyndwjd - Makeup, Face, Eyes, Lips, Tools Accessories, Makeup Sets Kits, Makeup Bags Accessories, Perfume Cologne, Women, Men, Unisex, Skin Care,...

By:

Follow this link:
Dovonex Cream For Psoriasis - Video

Holistic Remedies For Psoriasis - Remede De Grand Mere Pour Le Psoriasis
http://bit.ly/1vTI3lp Click here to learn how to cure psoriasis for good in less than 3 days. This method is easy and really does what it #39;s supposed to! Holistic remedies for psoriasis....

By: Hedy Ventimiglia

See more here:
Holistic Remedies For Psoriasis - Remede De Grand Mere Pour Le Psoriasis - Video

Following the companys recently-announced plans to merge its consumer technology and medtech divisions, Philips has just announced a new wearable medical device thats been clinically proven to control mild and moderate cases of psoriasis a skin condition that affects more than 125 million people worldwide.

In a nutshell, psoriasis is caused by the overly-rapid division of skin cells on the epidermis. This exceedingly fast division usuallyleads to the formation of scaly patches and plaques, which are oftentimes itchy and painful. To treat these symptoms, most people generally rely onmedicated creams and ointments, but Philips has developed a new approach.

The companys latest device, called BlueControl uses a wearable array of 40 high-intensity LEDs to shine specific wavelengths of blue light onto the affected areas of a persons body. This helps to slow down the cell division, and in a number of clinical trials was shown to reduce the symptoms of psoriasis vulgaris by an average of 50 percent.

Its worth noting that Philips isnt the first to explore the prospect of treating psoriasis with light therapy. Medical scientists have long understood the benefits of sunlight for those who suffer from the condition, and special lamps have even been developed to treat patients. That being said, however, BlueConnect is significant for two reasons: 1.) its doesnt use harmful ultraviolet light, and 2.) its designed to be used at home.

Related:Light-therapy bus shelters set to cheer up Swedes in winter

The device comes in the form of small, battery-powered light pod that fits into a wearable strap. This strap is fully adjustable and can be placed virtually anywhere on the body, meaning patients can use it in the comfort of their own homes and cut down on visits to the doctors office.

Philips says BlueConnect will be prescribed by physicians, and available through distributors in the Netherlands, Germany, and the UK starting this month. No word on when itll roll out in the US, but weve reached out to company representatives and well update this post with additional info as soon as we get it.

Read more here:
Philips unveils BlueControl: a device that fights psoriasis with light therapy

When you know how to explain your psoriasis to others, it can relieve some of the stress that goes along with your skin condition.

"The more people around you that know about it, the more support you'll get," says Linda Cornish. She's a dermatology nurse who helps people with psoriasis at Kaiser-Permanente Medical Center in Oakland, CA. "And being open and honest can make you feel less self-conscious."

These six tips can help you talk about your psoriasis to friends and coworkers.

1. Choose the right time.

Figure out a time and a place that will make you feel comfortable.

"If you're relaxed and at ease, the person you're talking to is more likely to feel at ease," says Julie Nelligan, PhD. She's a health psychologist in private practice in Portland, OR.

The right setting is likely to depend in part on the person you're talking to. With a coworker, you may want to bring up the subject during a break or over lunch. If you're talking to someone you've begun dating, you may want to arrange a special time.

2. Think through what you want to say.

Plan it out. That can help make things easier. Chances are you'll also feel more relaxed. How much detail you give will depend on the person you're talking with.

A coworker may need to know only what psoriasis is and that they cant catch it. Your boss might need to know about your treatments if that means taking time off from work. When talking to a date, you may want to explain what living with psoriasis is like for you.

See the rest here:
Talking About Your Psoriasis to Others

THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present several studies related to brodalumab, Enbrel (etanercept) and ABP 501 (adalimumab biosimilar) at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014. These data reinforce Amgen's continued commitment to delivering medicines that may help to improve the lives of people suffering from devastating dermatologic diseases.

"As a pioneer in psoriasis research and development, we are pleased to share scientific insights from our growing dermatology portfolio that may help improve care for the millions of people worldwide1 affected by this serious skin disease," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The data being presented at this year's congress demonstrate the breadth and depth of our biologics expertise in advancing treatments that address critical unmet needs for patients living with psoriasis."

Brodalumab data to be presented include an exploratory analysis of the Phase 2 trial evaluating efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis patients with prior biologic exposure, along with an analysis from the open-label extension study of that same Phase 2 study evaluating patient response to treatment after nearly three years. Brodalumab is being co-developed by Amgen and AstraZeneca. Kyowa Hakko Kirin, which has an exclusive license to develop and commercialize brodalumab in Japan, China and certain other Asian countries, will present efficacy and safety data from its Phase 2 study evaluating brodalumab in Japanese patients with moderate-to-severe plaque psoriasis.

ENBREL data focus on step-down dosing compared with a high-dose regimen and patient-reported outcomes of treatment with ENBREL compared to treatment with ENBREL in combination with topical therapies. Additional data include the functional equivalence of proposed biosimilar ABP 501 to adalimumab and an analysis of the incidence of symptoms such as itching and pain in patients with psoriasis.

SELECTED ABSTRACTS OF INTERESTAbstracts are available to registered journalists at http://www.eadvamsterdam2014.org/press and updated data will be presented at the meeting.

Brodalumab Abstracts of Interest

ENBREL (Amgen-sponsored) Abstracts of Interest

Biosimilars Abstracts of Interest

Additional Abstracts of Interest

About Psoriasis Psoriasis is a non-contagious chronic disease in which the immune system causes skin cells to grow at an accelerated rate.2 Instead of being shed, skin cells pile up, causing painful and itchy, red, scaly patches.3 Approximately 125 million people worldwide have psoriasis, and 80 percent of those patients have plaque psoriasis.1,4

See the rest here:
Amgen Announces Moderate-To-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy ...